Next-Generation Biomanufacturing Market Players:
- Sartorius AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Regeneron Pharmaceuticals, Inc.
- GEA Group Aktiengesellschaft
- PBS Biotech Inc.
- Applikon Biotechnology BV
- Danaher Corporation
- Merck KGaA
- Shanghai Bailum Biotechnology Co., Ltd.
- Solaris Biotechnology Srl.
- ZETA GmbH
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of next-generation biomanufacturing is evaluated at USD 27.65 billion.
The global next-generation biomanufacturing market size was worth over USD 25.71 billion in 2025 and is poised to grow at a CAGR of around 8.4%, reaching USD 57.6 billion revenue by 2035.
By 2035, the monoclonal antibodies segment in the next-generation biomanufacturing market is projected to secure a 48% share, underpinned by the accelerating adoption of next-generation biotechnological techniques for faster and more efficient mAb production.
Key players in the market include Sartorius AG, Regeneron Pharmaceuticals, Inc., GEA Group Aktiengesellschaft, PBS Biotech Inc., Applikon Biotechnology BV, Danaher Corporation, Merck KGaA, Shanghai Bailum Biotechnology Co., Ltd., Solaris Biotechnology Srl., ZETA GmbH.
